Terminated PHASE3 INTERVENTIONAL 1-arm NCT01135524

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

A Randomized, Double-blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain: A 52-Week Extension Phase

Sponsor: Purdue Pharma LP

Conditions Osteoarthritis

Interventions Buprenorphine transdermal patch

Updated 8 times since 2017 Last updated: Sep 5, 2012 Started: Apr 30, 2004 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated early for administrative reasons.

Other terminated trials from Purdue Pharma LP

See all terminations from Purdue Pharma LP

Other Osteoarthritis trials with similar outcome

Browse all Osteoarthritis trials

This PHASE3 trial investigates Osteoarthritis and is currently terminated or withdrawn. Purdue Pharma LP leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Purdue Pharma LP

Data source: Purdue Pharma LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alabaster, United States , Altoona, United States , Amarillo, United States , Baltimore, United States , Benzonia, United States , Birmingham, United States , Boise, United States , Bridgeport, United States , Brockton, United States , Buena Park, United States and 68 more locations